Authors: | Koon, H. B.; Fingleton, B.; Lee, J. Y.; Geyer, J. T.; Cesarman, E.; Parise, R. A.; Egorin, M. J.; Dezube, B. J.; Aboulafia, D.; Krown, S. E. |
Article Title: | Phase II AIDS malignancy consortium trial of topical halofuginone in AIDS-related kaposi sarcoma |
Abstract: | Using a novel blinded intrapatient vehicle control design, we conducted a phase II study of topically administered halofuginone, an angiogenesis inhibitor that inhibits collagen type-I and matrix metalloproteinases (MMPs), in patients with AIDS-related Kaposi sarcoma. Serial Kaposi sarcoma biopsies assessed treatment effects on angiogenic factors and Kaposi sarcoma herpesvirus-latency associated nuclear antigen-1 (KSHV-LANA). We observed marked heterogeneity of KSHV-LANA expression. Although the small number of subjects whose response could be evaluated precluded definitive assessment of halofuginone's efficacy, we observed a significant decrease in type-I collagen only in halofuginone-treated lesions, but no effect on MMP-2. The trial design is applicable to future studies of topical agents. © 2010 by Lippincott Williams & Wilkins. |
Keywords: | adult; clinical article; controlled study; treatment response; unclassified drug; clinical trial; drug efficacy; antigen expression; multiple cycle treatment; phase 2 clinical trial; tumor biopsy; collagen type 1; matrix metalloproteinase; acquired immune deficiency syndrome; kaposi sarcoma; human herpesvirus 8; gelatinase a; angiogenic factor; halofuginone; latency associated nuclear antigen; latency associated nuclear antigen 1; nsc 713205 |
Journal Title: | JAIDS: Journal of Acquired Immune Deficiency Syndromes |
Volume: | 56 |
Issue: | 1 |
ISSN: | 1525-4135 |
Publisher: | Lippincott Williams & Wilkins |
Date Published: | 2011-01-01 |
Start Page: | 64 |
End Page: | 68 |
Language: | English |
DOI: | 10.1097/QAI.0b013e3181fc0141 |
PROVIDER: | scopus |
PMCID: | PMC3017346 |
PUBMED: | 21068672 |
DOI/URL: | |
Notes: | --- - "Export Date: 4 March 2011" - "CODEN: JJASF" - "Source: Scopus" |